Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow VTVT by emailGet an email when VTVT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VTVT, unsubscribe in one click. Privacy
📣 What VTVT Says Is Next
year end 2026 · “Cadisegliatin Hybrid Closed-Loop Trial (Hybrid CATT1). vTv expects to initiate the Phase 2a Hybrid CATT1 trial before year end 2026.”
Company press release, Aug 6, 2026 · SEC filing
second half of 2026 · “Topline data from the study is expected in the second half of 2026.”
Company press release, Nov 6, 2025 · SEC filing
second half of 2026 · “With a strengthened balance sheet, we are positioned to continue advancing our cadisegliatin program and remain on track to report topline results from the CATT1 trial in the second half of 2026.” Recent Company Highlights”
Company press release, Nov 6, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full VTVT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VTVT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.